

# West Virginia Medicaid Drug Utilization Review Board Minutes

February 28, 2018

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

## **Members:**

Lester Labus, MD, Chair  
K.C. Lovin, PA-C, Vice Chair  
Mary Nemeth-Pyles, MSN, RN, CS  
Chris Terpening, PharmD, PhD  
Ernest Miller, DO  
Michael Ballow, PharmD  
Kate Forman, PharmD  
Michael Lonsinger, PharmD  
Myra Chiang, MD  
John Vanin, MD (via phone)  
John Guilfoose, MD (via phone)  
Scott Brown, RPh (via phone)  
Christopher Booth, PharmD (via phone)

## **Members Absent:**

C.K. Babcock, PharmD

## **DHHR/BMS Staff:**

Vicki Cunningham, RPh, Director of Pharmacy Services  
Brian Thompson, MS, PharmD, DUR Coordinator  
Lori Moles, RPh, Staff Pharmacist  
Bill Hopkins, Pharmacy Operations Manager  
Doug Sorvig, Administrative Assistant  
Gail Goodnight, RPh, Rebate Coordinator

## **Contract Staff:**

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)  
Eric Sears, RPh, Molina Medicaid Solutions  
Brent Breeding, RPh, Change Healthcare  
Taylor DeRuiter, PharmD, Health Information Designs (HID)

## **I. INTRODUCTIONS**

- A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting at 4:04 p.m. EDT. The DUR Board and attendees introduced themselves.

## II. APPROVAL OF MINUTES FROM November 15, 2017 DUR BOARD MEETING

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

## III. OLD BUSINESS

1. None

## IV. NEW BUSINESS

### A. Speakers

1. None

### B. Updates from the January 24, 2018 Pharmacy & Therapeutics Committee Meeting

1. Dr. Labus and the Board reviewed the updates from the January 24, 2018 P&T meeting. The Board requested that uses for lidocaine patches outside of post-herpetic neuralgia, as well as patterns of gabapentin use be evaluated and presented at the next meeting. No criteria changes were requested beyond those presented in section IV-C of this document.

### C. PDL Prior Authorization Criteria (Attachment A)

1. **Lyrica** – A motion to approve the criteria as presented was made, seconded, and passed.
2. **Gralise** – A motion was made to amend the presented criteria to change the requirement of a 90-day trial of a tricyclic antidepressant to only 30 days. A motion to approve the amended criteria was made, seconded, and passed.
3. **Savella** – A motion to approve the criteria as presented was made, seconded, and passed.
4. **Topical Antifungal/Steroid Combinations** – A motion to approve the criteria as presented was made, seconded, and passed.
5. **Trulance** – A motion to approve the criteria as presented was made, seconded, and passed.
6. **OFEV** – A motion to approve the criteria as presented was made, seconded, and passed.
7. **Humira/Enbrel** – A motion to approve the criteria as presented was made, seconded, and passed.
8. **Repatha** – A motion to approve the criteria as presented was made, seconded, and passed.
9. **Synagis** – A motion to approve the criteria as presented was made, seconded, and passed.

## V. REPORTS

- A. **Molina Quarterly Report** – Eric Sears presented an overview of the Molina 2017 Fourth Quarter Report (Attachment B). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. **Rational Drug Therapy Program** – Steve Small presented a review of the prior authorization program for the Fourth Quarter 2017. (Attachment C).
- C. **Health Information Designs** – Taylor DeRuiter presented an overview of the Fourth Quarter 2017 retrospective drug utilization activity (Attachment D). The

presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers. Additionally, topics for future population-based interventions were presented and the Board approved interventions: concomitant use of opioids and benzodiazepines and utilization of prescription narcotics in patients with a history of narcotic overdose/poisoning.

**VI. OTHER BUSINESS – OPEN TO THE FLOOR**

- A. None

**VII. NEXT MEETING AND ADJOURNMENT**

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:15 p.m. EDT.
- C. The next meeting will be Wednesday, May 23, 2018 from 4:00 p.m.–6:00 p.m. and located at WVDHR.

Submitted by:

Taylor DeRuiter, PharmD, Health Information Designs